drugset
drugset / Trial / NCT03330314

Molar Potency Study of HM12460A in Healthy Subjects

NCT03330314 ↗

Phase 1 Completed 38 enrolled Hanmi Pharmaceutical Company Limited
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a phase 1 study to assess and compare molar potency of HM12460A and glargine in healthy subjects.

Timeline

Start
2017-10-24
Primary completion
2018-02-08
Completion
2018-02-08

Drugs

EvaluationDrugModalityDoseRoute
Subject HM12460A Protein / enzyme biologic — Intravenous

Indications

No indication recorded.